Research programme: inhaled pirfenidone - Avalyn Pharmaceuticals

Drug Profile

Research programme: inhaled pirfenidone - Avalyn Pharmaceuticals

Alternative Names: Aerodone™; Aerosol pirfenidone; GP-101

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genoa Pharmaceuticals
  • Developer Avalyn Pharma; McMaster University
  • Class Antifibrotics; Pyridones; Small molecules
  • Mechanism of Action Collagen inhibitors; Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Idiopathic pulmonary fibrosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in USA (Inhalation, Aerosol)
  • 15 May 2017 Avalyn Pharmaceuticals plans a phase I trial for Idiopathic pulmonary fibrosis in Australia (Inhalation) in November 2017 (ACTRN12617001501336)
  • 05 Aug 2014 Inhaled pirfenidone receives Orphan Drug status for Idiopathic pulmonary fibrosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top